In Elsmere, Kentucky, 81-year-old Judith Gregory’s life took a distressing turn when she started experiencing severe discomfort in her left eye. This marked the beginning of her extensive and painful journey through medical treatments due to an eye infection. She believes the infection originated from contaminated over-the-counter eye drops, leading her to file a lawsuit against Global Pharma Healthcare, the India-based manufacturer.
The product in question, EzriCare Artificial Tears, was later identified as potentially contaminated with harmful bacteria. This alarming revelation was part of a broader recall by Global Pharma in February. The recall, which also included another eye drop brand, was linked to severe infections, some resulting in blindness, eye surgeries, and even fatalities.
The U.S. Food and Drug Administration (FDA) intensified the situation with a warning against more than two dozen eye drop variants from various brands. This included products from major retailers like CVS Health, Rite Aid, and Walmart. The warning underscored the lesser-known risks associated with over-the-counter eye care products.
A recent study published in the Journal of the American Medical Association Ophthalmology sheds light on the regulatory oversight gaps in the non-prescription drug market. Co-authored by Timothy Milton Janetos from Northwestern University, the paper reveals the challenges in assuring the safety of these widely used products. Milton emphasizes the difficulty in determining the safety of these eye drops due to inadequate regulatory mechanisms.
The recall of Global Pharma’s products brought to the forefront the FDA’s limitations in inspecting overseas manufacturing facilities, especially during the COVID-19 pandemic. The FDA’s delayed inspection of Global Pharma’s India-based factory revealed numerous safety violations.
The severity of the situation was highlighted by the Centers for Disease Control and Prevention’s (CDC) findings, which included cases of blindness, surgical removal of eyeballs, and deaths linked to the contaminated products.
In response to this health crisis, the FDA and the CDC have been working to address these regulatory shortcomings and improve the safety of over-the-counter drugs. This includes proposed legislative changes that would grant the FDA more authority to inspect drug manufacturing facilities before products are sold.
Eye care professionals and organizations like the American Academy of Ophthalmology (AAO) are advocating for more rigorous scrutiny of over-the-counter eye care products. They encourage consumers to remain vigilant about recalls and consult professionals when choosing eye care products.
CONTACT PARKER WAICHMAN LLP FOR A FREE CASE REVIEW
Regardless of your location or where your injury occurred, our nationwide personal injury law firm is ready to assist you.
Parker Waichman LLP helps families recover monetary compensation for harm caused by dangerous products. For your free consultation, contact our national product liability law firm today by using our live chat or calling 1-800-YOUR-LAWYER (1-800-968-7529).
.svg){kind=small}
.avif)
.avif)